Cytolytic Information and Courses from MediaLab, Inc.
These are the MediaLab courses that cover Cytolytic and links to relevant pages within the course.
Learn more about laboratory continuing education for medical technologists to earn CE credit for AMT, ASCP, NCA, and state license renewal and recertification. Or get information about laboratory safety and compliance courses that deliver cost-effective OSHA safety training and continuing education to your laboratory's employees.
|Staphylococcus aureus Virulence Factors|
S. aureus is the most pathogenic member of the genus Staphylococcus; it possesses several factors that contribute to its virulence: Structural components of its cell wall function as a protective barrier, aid in adherence to mucous membranes, and allow the organism to resist phagocytosis. The production of several different toxins Enterotoxins A, D, F (TSST1) Exfoliative toxin ( causing scalded skin syndrome Cytolytic toxins (causing cell & tissue damage). Production of enzymes Catalase – distinguishes staphylococci from streptococci Coagulase – distinguishes S. aureus from other staphylococci Hyaluronidase & lipase – aid in skin colonization/infection spread Beta-lactamase – breaks down the beta-lactam antibiotics, e.g., penicillins, cephalosporins, carbapenems and monobactams.
|Future Perspectives (continued)|
Judicious use of antimicrobials, especially in outpatient settings, can help control the emergence of CA-MRSA and limit the acquisition of additional resistance by existing strains. Regardless of origin, minimizing antibiotic selective pressure that favors the development of resistant strains is essential to controlling the emergence of these strains in both hospital and community settings.The development of vaccines to prevent S. aureus infection in both healthcare and community settings holds great promise. Recently (2007) a vaccine based on an immunotherapeutic licensed to Merck has shown promising results in a clinical trial against hospital acquired S. aureus infections, while Nabi Biopharmaceuticals, Ft. Lauderdale, FL, are developing the "next generation" of StaphVax, which will contain antigen against S. aureus detoxified Panton Valentine Leucocidin and the cytolytic alpha-toxin.